Gregory Longmore, MD

Medical School Department Internal Medicine
Research Program Mechanisms of Cancer Biology Program
Gregory Longmore

Researcher Background

Primary Academic Title

Professor of Medicine, Division of Oncology, and Co-Director, Section of Molecular Oncology, WashU Medicine

Training

  • 1983 - 1985: Intern and Resident, Internal Medicine, New England Deaconess Hospital and Harvard Medical School, Boston, MA
  • 1985 - 1986: Visiting Scientist, Massachusetts Institute of Technology, Boston, MA
  • 1986 - 1987: Chief Resident, Internal Medicine, New England Deaconess Hospital and Harvard Medical School, Boston, MA
  • 1987 - 1988: Clinical Fellow, Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA
  • 1987 - 1990: Clinical Fellow, Hematology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
  • 1988 - 1992: Postdoctoral Research Fellow, Whitehead Institute for Biomedical Research and Massachusetts Institute of Technology, Cambridge, MA

Education

  • 1979: MS, University of Toronto, Toronto, ON
  • 1983: MD, McGill University, Montreal, QC

Research & Selected Publications

Research Interest

The Longmore laboratory major research focus is to determine how tumor cells and their immediate environment communicate with one another to facilitate tumor cell invasion, migration, and metastasis. In general, Cell adhesions and Cell Migration. The laboratory has identified and validated a number of novel pathways and putative targets with the potential for development of novel therapeutics. We use multidisciplinary approaches that include: molecular cell biology, mechanobiology, computational simulation, and various live 3D imaging modalities.

Research Publications

Cadherin-1-mediated communication at the leader-follower boundary controls mouse breast tumor organoid collective migration.
Authors:

Morikis VA, Avila DB, DiMauro A, one or more additional authors omitted Longmore GD

Journal & Year:

Cell Rep • 2025

DDR2 Confers Ferroptosis Resistance to Cancer-Associated Fibroblasts and Attenuates PARPi Sensitivity of Ovarian Tumor Cells.
Authors:

Lesage J, DiMauro A, Schab AM, one or more additional authors omitted Longmore GD

Journal & Year:

Mol Cancer Res • 2025

Senescent CAFs Mediate Immunosuppression and Drive Breast Cancer Progression.
Authors:

Ye J, Baer JM, Faget DV, one or more additional authors omitted Longmore GD, one or more additional authors omitted Stewart SA

Journal & Year:

Cancer Discov • 2024

ROR2/Wnt5a Signaling Regulates Directional Cell Migration and Early Tumor Cell Invasion in Ovarian Cancer.
Authors:

Grither WR, Baker B, Morikis VA, one or more additional authors omitted Longmore GD

Journal & Year:

Mol Cancer Res • 2024